[go: up one dir, main page]

CL2019000273A1 - Composición mejorada de teneligliptina y metformina y proceso para prepararla. - Google Patents

Composición mejorada de teneligliptina y metformina y proceso para prepararla.

Info

Publication number
CL2019000273A1
CL2019000273A1 CL2019000273A CL2019000273A CL2019000273A1 CL 2019000273 A1 CL2019000273 A1 CL 2019000273A1 CL 2019000273 A CL2019000273 A CL 2019000273A CL 2019000273 A CL2019000273 A CL 2019000273A CL 2019000273 A1 CL2019000273 A1 CL 2019000273A1
Authority
CL
Chile
Prior art keywords
metformin
distribution
improved
active
excipients
Prior art date
Application number
CL2019000273A
Other languages
English (en)
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61196457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000273(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of CL2019000273A1 publication Critical patent/CL2019000273A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2019000273A 2016-08-17 2019-02-01 Composición mejorada de teneligliptina y metformina y proceso para prepararla. CL2019000273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016010682A MX384961B (es) 2016-08-17 2016-08-17 Composición mejorada de teneligliptina y metformina y proceso para prepararla.

Publications (1)

Publication Number Publication Date
CL2019000273A1 true CL2019000273A1 (es) 2019-06-28

Family

ID=61196457

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000273A CL2019000273A1 (es) 2016-08-17 2019-02-01 Composición mejorada de teneligliptina y metformina y proceso para prepararla.

Country Status (8)

Country Link
AR (1) AR109253A1 (fr)
CL (1) CL2019000273A1 (fr)
CO (1) CO2019001110A2 (fr)
DO (1) DOP2019000035A (fr)
EC (2) ECSP19010066A (fr)
MX (1) MX384961B (fr)
PE (1) PE20190402A1 (fr)
WO (1) WO2018033808A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques
WO2015132679A1 (fr) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Compositions de ténéligliptine

Also Published As

Publication number Publication date
BR112019002909A2 (pt) 2019-05-21
AR109253A1 (es) 2018-11-14
DOP2019000035A (es) 2019-06-30
MX384961B (es) 2025-03-14
CO2019001110A2 (es) 2019-04-12
MX2016010682A (es) 2018-02-16
PE20190402A1 (es) 2019-03-13
ECSP19044926A (es) 2019-07-31
WO2018033808A1 (fr) 2018-02-22
ECSP19010066A (es) 2019-11-30

Similar Documents

Publication Publication Date Title
AR134152A2 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2020002647A2 (es) Composiciones de glp-1 y sus usos
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CL2019000571A1 (es) Formulaciones de carbamato de (r) -2-amino-3-fenilpropilo.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016011038A (es) Compuestos para el tratamiento de trastornos mediados por complemento.
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
ECSP17085669A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
PE20200746A1 (es) AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2022002667A (es) Composicion oftalmica para el tratamiento de uveitis.
CO2021014755A2 (es) Compuestos inhibidores de la masp y usos de estos
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
CL2019000273A1 (es) Composición mejorada de teneligliptina y metformina y proceso para prepararla.
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением